2013 has been a great year in the world of pharma and biotech R&D. While we are still facing mounting productivity challenges, many have come to understand that no single company – no matter how committed to patients – can overcome these challenges on its own. Open and collaborative approaches are creating waves of change and new horizons of opportunity on global scale. Into 2014, how would external forces shape our solutions for patients? And how can we, collectively, propel our industry fast forward?
AGENDA January 14, 2014 | Ballroom East, Grand Hyatt San Francisco (345 Stockton St, San Francisco, CA 94108)
Registration and Networking
, Forum Chair; VP of Corporate Alliances and Head of Communications, WuXi AppTec
Session I: Industry in Change
Moderator: David Flores
, Co-Founder, President & CEO, Biocentury
, SVP of Business Development, Celgene
, Managing Partner, 5AM Ventures
, Founder, Chairman & CEO, 2M Companies; Chairman & CEO, 2M BioTech
Session II: Is R&D on Track?
Moderator: Richard Soll
, SVP of Integrated Services and Head of Corporate Alliances, WuXi AppTec
, President of R&D, Servier
, EVP and Global Head of R&D, Alexion Pharmaceuticals
, COO and CFO, WuXi AppTec
Session III: Spotlight on China
Moderator: Greg Scott,
Founder and CEO, ChinaBio
, Senior Manager Partner, Orbimed Asia
, Executive Director of Business Development, BMS
, Chief Executive Officer, ASLAN Pharmaceuticals
Vice President of Corporate Alliances
Head of PR and Corporate Communications, WuXi AppTec
Dr. Hui Cai joined WuXi AppTec in 2009 as Vice President of Business Development, and is currently Vice President of Corporate Alliances and Head of PR and Corporate Communications.
Prior to WuXi, Dr. Cai spent 10 years at Johnson & Johnson Pharmaceutical Research and Development leading multiple drug discovery programs in the therapeutic areas of inflammation and autoimmune diseases. She is a co-author and co-inventor to over 40 scientific publications and issued or pending patents. Dr. Cai is a Councilor of the American Chemical Society (ACS) and a member of ACS national committee on Chemistry and Public Affairs. She is also a member of the Advisory Council of UCSD IRPS 21th Century China Program, and a member of BayHelix. In her past capacity, she served as a Commissioner at the City of San Diego Science and Technology Commission, Chair of SABPA, and President of SDCA. Dr. Cai received her BS and MS in Chemistry from Peking University, PhD from The Scripps Research Institute, and MBA from UCSD Rady School of Management as a DLA Piper – Athena Scholar.
Session I: Industry in Change
Co-Founder, President & CEO, Biocentury
Mr. David Flores has devoted more than two decades to developing information products for biotechnology executives and investors. He is a graduate of the University of California at Berkeley and holds an MBA from Stanford University.
Mr. Flores is a member of the Advisory Board of the Innovation and New Ventures Office (INVO) at Northwestern University and a member of the Advisory Council of the Keck Graduate Institute of the Applied Life Sciences. He also has served as a member of the Stanford Graduate School of Business Management Board. In 1996, Mr. Flores and BioCentury Co-Founder, Chairman & Editor-in-Chief Ms. Karen Bernstein were honored with the Special Recognition Award given by the annual gathering of biotechnology chief executive officers in Laguna Niguel, Calif., citing BioCentury’s ongoing contributions to the industry.
SVP of Business Development, Celgene
Dr. George Golumbeski is currently Senior Vice President of Business Development for Celgene Corporation, where he is responsible for the full array of business development activities (identification & evaluation of opportunities, structuring & negotiating transactions, in-licensing, M&A, outlicensing, and alliance management).
At Celgene, these activities are focused within the therapeutic areas of oncology and inflammation. Prior to Celgene, Dr. Golumbeski served as Vice President of Business Development, Licensing and Strategy for Novartis-Oncology. During his tenure at Novartis, Dr. Golumbeski’s group closed a significant number of collaboration agreements which bolstered the development pipeline. Earlier in his career, Dr. Golumbeski held senior positions at Elan Pharmaceuticals and at Schwarz Pharma, where he led the effort to in-license rotigotine and lacosamide (both now approved agents). In most of his positions, Dr. Golumbeski has served on the R&D and/or Corporate Leadership Teams. Dr. Golumbeski received a BA in Biology from the University of Virginia, a PhD in Genetics from the University of Wisconsin-Madison. He has spoken frequently at industry conferences and leading business schools on a variety of topics related to the collaborations within the biopharmaceutical industry.
Managing Partner, 5AM Ventures
Mr. Andrew Schwab is a Founder and Managing Partner of 5AM Ventures.Prior to founding 5AM in 2002, Mr. Schwab was a Principal at Bay City Capital. At 5AM, he has led the firm’s investments in and served on the Boards of Directors of Biodesy, Cleave, DVS, Flexion, Ikaria, Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed), Panomics (acquired by Affymetrix), RuiYi, Synosia (acquired by Biotie) and Viveve.
After joining Bay City Capital in 1999, he led the firm’s investment and merchant banking activities for such companies as Cubist, Metabolex, PTC Therapeutics, Symyx and Syrrx.Previously Mr. Schwab was Vice President of Business Development at Digital Gene Technologies and a Vice President in the life science investment banking group of Montgomery Securities. Mr. Schwab received a B.S. with Honors in Genetics & Ethics from Davidson College and was a member of Davidson’s 1992 Final Four soccer team. Mr. Schwab is based in the Menlo Park, CA office.
Founder, Chairman & CEO, 2M Companies
Chairman & CEO, 2M BioTech
Mr. Morton Meyerson is the Founder, Chairman and CEO of 2M Companies, a full service holding company for a family office and foundation. He is also Chairman and CEO of 2M BioTech, a drug development company leveraging a broad network of expertise in drug development, financing, patent protection, startup development, marketing and communications.
Mr. Meyerson received a BA degree from University of Texas Austin majoring in Economics and Philosophy, and began his career in 1963 at Bell Helicopter after serving 2 years in the US Army as a Data Processing Officer. In 1966, he joined Electronic Data Systems (EDS) as a systems engineer trainee, ultimately becoming President and Vice Chairman and managing 45,000 employees. In 1984, Mr. Meyerson played a significant role in the sale of EDS to General Motors for $2.5 billion, becoming the top technology officer at General Motors. From 1971 through 1974, during his tenure at EDS and at the age of 33, Mr. Meyerson was the Chairman and CEO of duPont Glore Forgan, a Wall Street brokerage firm. During 1986-1992, Mr. Meyerson pursued private investment opportunities with Richard Rainwater who was the personal coach for Michael Dell in the early years of Dell Computer during 1988-1992. In 1992, at the request of Ross Perot, Mr. Meyerson re–joined the corporate world as the Chairman and CEO of Perot Systems Corporation. Mr. Meyerson has received the distinction of outstanding Chief Executive Officer from The Wall Street Transcript three times, and was elected into The American Academy of Arts & Sciences 2007 Class of Fellows.
Session II: Is R&D on Track?
SVP of Integrated Services and Head of Corporate Alliances, WuXi AppTec
Dr. Richard Soll is SVP of Integrated Services and Head of Corporate Alliances at WuXi AppTec. In this capacity, Dr. Soll has advanced more than 30 programs across major target classes and therapeutic indications from hits through lead optimization campaigns to clinical candidates on behalf of WuXi collaborators.
In addition, Dr. Soll heads Corporate Alliances Office at WuXi, overseeing strategic partnerships. Prior to WuXi, Dr. Soll was CSO and VP of R&D at TargeGen where he led multiple clinical stage R&D programs. Prior to TargeGen, Dr. Soll founded the chemistry department at 3-Dimensional Pharmaceuticals as VP of Chemistry. Dr. Soll began his industry career at Wyeth Pharmaceuticals, and was trained as a synthetic chemist at Dartmouth and Harvard. Dr. Soll’s drug discovery and development experiences has led to more than 100 patents and papers, and 8 drug candidates advancing to the clinic including drugs of breakthrough designation. Dr. Soll has been an SAB member to biotech companies and a or to entrepreneurs.
President of R&D, Servier
Dr Emmanuel Canet was trained in France and then Canada, and has spent the majority of his industrial career with the group Servier where he has been the President of Research and Development since September 2007.
In this role, Dr. Canet provides vision, leadership, and management of Servier’s R&D organization that focuses on the unmet medical needs in cardiovascular, metabolic, neurological, psychiatric and bone and joint diseases, as well as oncology. Established in 140 countries worldwide with over 20,000 employees and a 2012 turnover of €3.9 billion, Servier is a leading French research-based pharmaceutical company, investing 25% of its turnover in R&D.
EVP and Global Head of R&D, Alexion Pharmaceuticals
Dr. Martin Mackay joined Alexion in May 2013 as EVP and Global Head of Research & Development. In his role, Dr. Mackay is focused on significantly expanding Alexion’s global R&D organization, with a goal of accelerating the simultaneous development of multiple life-transforming drug candidates in debilitating and life-threatening ultra-rare disorders across a range of therapeutic areas.
Prior to joining Alexion, Dr. Mackay served as President, Research and Development at AstraZeneca, where he led all R&D functions worldwide, including discovery research, clinical development, regulatory affairs and key related R&D functions. He also held positions of increasing responsibility at Pfizer, rising to the position of President, Head of Pfizer Pharmatherapeutics, R&D, where he oversaw all aspects of small molecule discovery and development across multiple therapeutic areas. Earlier in his career, Dr. Mackay worked in the CIBA organization (now Novartis) and held positions within academia. Dr. Mackay earned a Microbiology First Class Honors Degree from Heriot-Watt University, Scotland, and a Ph.D. in Molecular Genetics from the University of Edinburgh, Scotland.
COO and CFO, WuXi AppTec
Mr. Edward Hu is currently COO and CFO at WuXi AppTec. In this capacity, Mr. Hu provides vision and oversight of new business and capability building, operational efficiency, organizational growth, and to ensure company’s financial health. In addition, Mr. Hu is Head of WuXi Corporate Venture Fund, spearheading the fund’s investment strategy and portfolio management.
Prior to joining WuXi, Mr. Hu was SVP and COO at Tanox, responsible for operations, finance, IT, project management and strategic planning, and managed the acquisition of Tanox by Genentech in 2007. He also held positions at Merck & Co., Inc. as a Senior Financial Analyst and later in Business and Financial Planning at Biogen, Inc. (n/k/a Biogen Idec, Inc.), where he managed the long range business planning of Biogen’s R&D and clinical operations, and provided project planning and analysis support to key drug development project teams. Mr. Hu completed his Ph.D. work, all but dissertation, in Biophysics and Biochemistry at Carnegie Mellon University, where he also received his M.B.A.
Session III: Spotlight on China
Founder and CEO, ChinaBio
Mr. Greg Scott founded ChinaBio LLC in January 2007 to bring together Chinese and Western life science companies to better leverage China’s rapidly growing life science markets. ChinaBio works with U.S. and European companies seeking partnerships, acquisitions, novel technologies and funding in China.
ChinaBio has also organized over 30 conferences in China focused on investment and partnering. Mr. Scott is also co-founder of two angel investment groups that have funded over 45 biotechnology and medical device companies in the U.S. and China since 2005, and Executive Editor of ChinaBio. Today, the most widely read source for China life science news. Mr. Scott lives and works in Shanghai but visits the U.S. several times a year to enjoy California’s blue sky and sandy beaches.
Senior Manager Partner, Orbimed Asia
With over 20 years of life sciences experience spanning VC, entrepreneurship and research, Dr. Jonathan Wang has cofounded OrbiMed Asia. Previously, he was a Partner at Legend Capital and General Manager at Burrill Greater China Group.
He also worked for WI Harper as a Managing Director, and Walden International. He was a Board Director at ForteBio and is a Board Director at EA, Inc., Response Biomedical Corporation and Bonovo Orthopedics. Dr. Wang is a co-founder and former Chairman of BayHelix, a premier group of Chinese life sciences business leaders. He holds a Ph.D. in Molecular Neurobiology from Columbia University, where he conducted research with of Eric Kandel, a Nobel Laureate. Dr. Wang received the Howard Hughes Medical Institute (HHMI) Research Fellowship at Columbia University. He also earned an M.B.A. from Stanford University.
Executive Director of Business Development, BMS
Dr. Jie D’Elia joined BMS in 2013 as an Executive Director of Business Development where she will serve as the global head of China strategic transactions. Prior to BMS, she was the Corporate Vice President of Business Development and Investor Relations at Simcere Pharmaceutical.
In 2011, Dr. D’Elia led the transaction to form the Simcere – Merck Joint Venture, a transformational deal that leverages a creative business model to deliver high quality off-patent drugs to the broader markets at affordable prices in China. Dr. D’Elia also created an innovative deal structure that led to a broad, multi-product, strategic partnership between Simcere and BMS. Prior to Simcere, Dr. D’Elia served as the Director of Business Development and New Product Planning at AstraZeneca China, where she directed the licensing initiatives and the planning efforts for AstraZeneca’s late-stage products in the China market. Previously, Dr. D’Elia worked as a Senior Manager of Business Development at Nastech Pharmaceutical and a Consultant at the New York office of the Boston Consulting Group. Dr. D’Elia holds a Ph.D. in Pharmaceutical Sciences from the University of Texas at Austin and an M.B.A. from Columbia Business School.
CEO, ASLAN Pharmaceuticals
Dr Carl Firth is CEO and Founder of ASLAN Pharmaceuticals. Previously, he was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies across the region and advising on M&A transactions.
Prior to joining the banking industry, he worked in China and Asia for 4 years leading business development, strategic projects and the development of new products. Dr. Firth has held positions in other commercial areas in the UK, including acquisitions, licensing and competitive intelligence, and has over 5 years of pharmaceutical R&D experience. Dr. Firth holds a PhD from Cambridge University in Molecular Biology and an Executive MBA from London Business School.